This annual event provides an opportunity for FDA and CMS/CLIA representatives to respond to member questions and present the agency's current thinking on policies, regulations, guidance documents and inspection programs that are relevant to the oversight of blood and HCT/P programs. Questions for the session are submitted in advance to email@example.com.
All relevant financial relationships have been mitigated.
Evaluate existing practices to establish alignment with current regulatory requirements and recommendations.
Apply FDA's recommendations in recently issued guidance to industry.
Describe FDA's approach for blood and HCT/P policies, regulations and inspection programs.